Drug Clinical Trials List

Share page

Display 1 - 10 from 730
Study Title Study Sponsor Status Study Drug Trial Phase Study Protocol Number Site
Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects with Severe or Moderately Severe Hemophilia B with Detectable Pretreatment AAV5 Neutralizing Antibodies CSL Behring LLC Ongoing HEMGENIX (etranacogene dezaparvovec) 3b CSL222_3005 King Faisal Specialist Hospital and Research Center (Riyadh)
Long-term pain and adherence observational study for Endometriosis treatment Abbott Ongoing Duphaston 4 DYDR-522-0318 Dr.Arab Clinic
Real world Assessment of Dyslipidemia patients on Inclisiran effiCacy And toLerability: The RADICAL Study Novartis Ongoing LEQVIO 4 CKJX839A1S Dallah Hospital (Riyadh)
Effect of celecoxib on postoperative narcotic use and disease severity in patients with aspirin-exacerbated respiratory disease and chronic rhinosinusitis: a randomized controlled trial King Khalid University Hospital Ongoing Celecoxib 4 114809 King Khalid University Hospital (Riyadh), King Abdulaziz University Hospital (Riyadh)
EASi-HF - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) >40% Boehringer Ingelheim Ongoing BI 690517 , empagliflozin 3 1378-0020 King Fahad Medical City (Riyadh), King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh)
Effect of Probiotics “Psychobiotics” on Depression in Adults with Obesity and Metabolic Syndrome in Riyadh City King Khalid University Hospital Ongoing Winclove’s Ecologic® Barrier probiotics 3 E-23-7867 King Khalid University Hospital (Riyadh)
A Phase 3 Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) Janssen Research & Development Rejected Nipocalimab 3 80202135EBF3001 King Faisal Specialist Hospital and Research Center (Riyadh), King Saud Medical City (Riyadh), King Fahad University Hospital (Al-Khobar)
REAL-WORLD, LONG-TERM DATA COLLECTION TO GAIN CLINICAL INSIGHTS INTO ROCHE OPHTHALMOLOGY PRODUCTS (VOYAGER STUDY)- COMPLETE Roche Ongoing Vabysmo 4 MR41927 King Abdulaziz Medical City NG (Jeddah)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy (IgAN) Biogen Idec Research Limited Ongoing Litifilimab 3 230LE305 King Faisal Specialist Hospital and Research Center (Riyadh)
A Multicenter, Open-label, Single-arm, Phase 3 Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 (Litifilimab) in Adult Participants with Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus with or without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST LTE) Biogen Idec Research Limited Ongoing Litifilimab 3 230LE305 King Faisal Specialist Hospital and Research Center ,(Riyadh) King Khalid University Hospital (Riyadh)


هل استفدت من ما هو مقدم في هذه الصفحة؟
0 من الزوار ردوا بنعم من أصل0 مشاركة
السبب
السبب